首页> 外国专利> Fusion protein comprising ccl3 variant and use thereof cross-reference to related applications

Fusion protein comprising ccl3 variant and use thereof cross-reference to related applications

机译:包含ccl3变体的融合蛋白及其在相关应用中的交叉引用

摘要

Provided is a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof. More particularly, a fusion protein comprising a wild-type human CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection. In a particular embodiment, the CCL3 variant comprises SEQ ID NO: 3 and comprises the following mutations: 1) deletion of N-terminal amino acid(s) alanine, or alanine and proline, and 2) substitution of aspartic acid to alanine at position 27. The CCL3 variant is linked to the Fc fragment with a linker having the following formula: (RNT)nGRGG(EEKKK)m wherein n and m are respectively 1 to 5.
机译:提供了具有改善的体内持久性,蛋白质稳定性和药理活性的CCL3变体的融合蛋白及其用途。更特别地,包含野生型人CCL3变体和免疫球蛋白Fc区的融合蛋白及其在淋巴细胞减少,癌症或感染的治疗剂中的用途。在一个特定的实施方案中,CCL3变体包含SEQ ID NO:3并包含以下突变:1)缺失N-末端氨基酸丙氨酸或丙氨酸和脯氨酸,和2)天冬氨酸在位置处被丙氨酸取代27.CCL3变体通过具有下式的连接子与Fc片段连接:(RNT)nGRGG(EEKKK)m其中n和m分别为1至5。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号